Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Diabetes

Additional Insulin Glargine Now Available in the United States

Diana Ernst, RPh

September 3, 2020

The long-acting human insulin analogue has an identical amino acid sequence to Lantus® (insulin glargine; Sanofi).

General Endocrinology

ACIP: Influenza Vaccination Recommendations for 2020-2021

Diana Ernst, RPh

August 25, 2020

Influenza vaccination should occur by the end of October, if possible.

General Endocrinology

FDA: Risk for Methanol Toxicity With Certain Hand Sanitizers

Diana Ernst, RPh

July 24, 2020

Hand sanitizers containing methanol, or wood alcohol, present a danger to individuals as the substance can be toxic when absorbed through the skin or life-threatening if ingested.

Diabetes

FreeStyle Libre 2 Cleared for Use in Adults and Pediatric Patients With Diabetes

Diana Ernst, RPh

June 18, 2020

The FDA has approved the FreeStyle® Libre 2 integrated continuous glucose monitoring system (Abbott) for adults and children ≥4 years of age with diabetes.

Cardiovascular and Metabolic Disorders

Combination Therapy of Bempedoic Acid, Ezetimibe Now Available as Adjunct to Statins

Diana Ernst, RPh

June 10, 2020

Nexlizet (bempedoic acid and ezetimibe; Esperion) is now available for use as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

Androgen and Reproductive Disorders

FDA Approves Treatment for Heavy Menstrual Bleeding Due to Uterine Fibroids

Diana Ernst, RPh

June 3, 2020

The FDA has approved Oriahnn™ (elagolix, estradiol, and norethindrone acetate capsules; elagolix capsules; AbbVie) for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women.

Type 2 Diabetes

FDA: Unacceptable NDMA Levels Identified in Certain Metformin ER Products

Diana Ernst, RPh

June 2, 2020

Specifically, unacceptable levels of this potentially carcinogenic impurity have been identified in products manufactured by 5 different firms.

Diabetes

Dasiglucagon Under Review for Severe Hypoglycemia

Diana Ernst, RPh

June 1, 2020

The FDA has accepted for review the New Drug Application for dasiglucagon HypoPal® Rescue Pen (Zealand Pharma) for the treatment of severe hypoglycemia.

General Endocrinology

FDA Updates Essure Adverse Events Page to Include 2019 Reports

Diana Ernst, RPh

May 8, 2020

The FDA has updated its “Problems Reported with Essure” webpage to include medical device reports received in 2019.

Pediatric Endocrinology

Leuprolide Acetate Approved for Central Precocious Puberty

Diana Ernst, RPh

May 6, 2020

The FDA has approved Fensolvi (leuprolide acetate; Tolmar Pharmaceuticals) for the treatment of pediatric patients 2 years of age and older with central precocious puberty.

Next post in Pediatric Endocrinology